Jenny Lam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jenny Lam has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan Salcedo
Affiliation Analysis Group, Inc., Boston, MA, United States of America
2 shared publications - Ahmad Masri
Knight Cardiovascular Institute, Oregon Health and Science University
1 shared publication - Amy J. Sehnert
Bristol Myers Squibb Princeton New Jersey USA
1 shared publication - Andrew Wang
Department of Cardiology, Duke University, Durham, NC (A.W.).
1 shared publication - Ankita Adhia
Actelion Pharmaceuticals US, Inc., a Johnson & Johnson company, San Francisco, CA
1 shared publication Biana Trost
North Shore Long Island Jewish
1 shared publication
Latest Publications
- Open Access
- 1 April 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (2) , e70294
Use of Machine‐Learning Models to Identify Clinical Features Associated With A Future Clinical Worsening Event in Patients With Pulmonary Arterial Hypertension
Clinical worsening events are increasingly recognized as a meaningful outcome in pulmonary arterial hypertension (PAH). We applied machine‐learning models to real‐world data to identify clinical features that may predict clinical worsening events in PAH. Data were obtained retrospectively from the electronic health records of adults diagnosed with PAH at Mayo Clinic locations (January 2015–December 2019). Machine‐learning LASSO regularized logistic regression models were developed to analyze the association between 100 clinical features and occurrence of clinical worsening events. In total, 455 patients were included (mean age 62.1 years; 59.3% female). Of these, 232 (51.0%) experienced a clinical worsening event after a median (quartile 1, quartile 3) of 10.9 (4.1, 21.4) months. The best‐performing model had an area under the curve of 0.78, sensitivity of 78%, and specificity of 59%. The model identified 11 clinical features associated with clinical worsening events in PAH with a non‐zero coefficient: baseline age, body mass index (BMI), creatinine level, red cell (erythrocyte) distribution width (RDW), mean pulmonary arterial pressure, pulmonary vascular resistance, sodium concentration, and QT interval, along with dyspnea, number of clinic visits, and other forms of heart disease within a 1‐month window before a clinical worsening event. Baseline RDW and BMI, and number of clinic visits within the 1‐month window were statistically significantly associated with clinical worsening events. Our study used machine‐learning models to identify clinical features associated with risk of clinical worsening events in PAH. Automation of risk prediction could lead to earlier therapeutic intervention to optimize patient outcomes.
- 1 April 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (2) , e70294
Open AccessUse of Machine‐Learning Models to Identify Clinical Features Associated With A Future Clinical Worsening Event in Patients With Pulmonary Arterial Hypertension
Clinical worsening events are increasingly recognized as a meaningful outcome in pulmonary arterial hypertension (PAH). We applied machine‐learning models to real‐world data to identify clinical features that may predict clinical worsening events in PAH. Data were obtained retrospectively from the electronic health records of adults diagnosed with PAH at Mayo Clinic locations (January 2015–December 2019). Machine‐learning LASSO regularized logistic regression models were developed to analyze the association between 100 clinical features and occurrence of clinical worsening events. In total, 455 patients were included (mean age 62.1 years; 59.3% female). Of these, 232 (51.0%) experienced a clinical worsening event after a median (quartile 1, quartile 3) of 10.9 (4.1, 21.4) months. The best‐performing model had an area under the curve of 0.78, sensitivity of 78%, and specificity of 59%. The model identified 11 clinical features associated with clinical worsening events in PAH with a non‐zero coefficient: baseline age, body mass index (BMI), creatinine level, red cell (erythrocyte) distribution width (RDW), mean pulmonary arterial pressure, pulmonary vascular resistance, sodium concentration, and QT interval, along with dyspnea, number of clinic visits, and other forms of heart disease within a 1‐month window before a clinical worsening event. Baseline RDW and BMI, and number of clinic visits within the 1‐month window were statistically significantly associated with clinical worsening events. Our study used machine‐learning models to identify clinical features associated with risk of clinical worsening events in PAH. Automation of risk prediction could lead to earlier therapeutic intervention to optimize patient outcomes.
- Open Access
- 7 March 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (7) , 1123-1132
Methamphetamine-associated PAH on the rise in the US: geographic trends & disparities in patient demographics and treatment strategies
- 7 March 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (7) , 1123-1132
Open AccessMethamphetamine-associated PAH on the rise in the US: geographic trends & disparities in patient demographics and treatment strategies
- Open Access
- 5 November 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (19) , 1560-1562
Association of Echocardiographic Parameters and Health Status in Patients With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM
- 5 November 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (19) , 1560-1562
Open AccessAssociation of Echocardiographic Parameters and Health Status in Patients With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM
- 1 February 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 62 (4) , 1224-1231.e5
Association of cash payment with intensity of opioid prescriptions
- 1 February 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 62 (4) , 1224-1231.e5
Association of cash payment with intensity of opioid prescriptions
- Open Access
- 22 December 2021
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 25 (1) , 51-58
Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial
To assess the effects of mavacamten on health-related quality-of-life (HRQoL) in symptomatic obstructive hypertrophic cardiomyopathy (HCM) and estimate health utilities by New York Heart Associatio...
- 22 December 2021
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 25 (1) , 51-58
Open AccessAssessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial
To assess the effects of mavacamten on health-related quality-of-life (HRQoL) in symptomatic obstructive hypertrophic cardiomyopathy (HCM) and estimate health utilities by New York Heart Associatio...
- Open Access
- 10 May 2021
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 11 (3) , 239-250
Memory Care Approaches to Better Leverage Capacity of Dementia Specialists: A Narrative Synthesis
Prior research suggests that a scarcity of dementia specialists could hamper access to disease-modifying Alzheimer’s treatments. We describe alternative approaches on how to leverage specialist tim...
- 10 May 2021
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 11 (3) , 239-250
Open AccessMemory Care Approaches to Better Leverage Capacity of Dementia Specialists: A Narrative Synthesis
Prior research suggests that a scarcity of dementia specialists could hamper access to disease-modifying Alzheimer’s treatments. We describe alternative approaches on how to leverage specialist tim...
- 8 March 2019
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 60 (10) , 2464-2470
Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States
While the initial hospitalization accounts for 75% of total healthcare costs during the first 100 days following hematopoietic stem cell transplantation (HSCT), there is a lack of studies evaluating the considerable variation in cost estimates. Using the National Inpatient Sample (NIS) database from 2012–2014, we identified 1832 adult non-Hodgkin lymphoma (NHL) patients who received autologous or allogeneic HSCT and examined complications as predictors of hospital cost. Complications occurred in >70% of patients, and the presence of one or more complications was associated with an increase in mean hospital costs of 46% in autologous HSCT and 81% in allogeneic HSCT. The most common complications (∼40%) were mucositis, febrile neutropenia, and infection. Acute organ failure, acute graft-versus-host disease, and death were less frequent (∼10%) but had a greater impact on increasing hospital costs and length of stays. Despite recent advances in supportive care and pre-conditioning regimens, complications are common and costly during HSCT.
- 8 March 2019
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 60 (10) , 2464-2470
Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States
While the initial hospitalization accounts for 75% of total healthcare costs during the first 100 days following hematopoietic stem cell transplantation (HSCT), there is a lack of studies evaluating the considerable variation in cost estimates. Using the National Inpatient Sample (NIS) database from 2012–2014, we identified 1832 adult non-Hodgkin lymphoma (NHL) patients who received autologous or allogeneic HSCT and examined complications as predictors of hospital cost. Complications occurred in >70% of patients, and the presence of one or more complications was associated with an increase in mean hospital costs of 46% in autologous HSCT and 81% in allogeneic HSCT. The most common complications (∼40%) were mucositis, febrile neutropenia, and infection. Acute organ failure, acute graft-versus-host disease, and death were less frequent (∼10%) but had a greater impact on increasing hospital costs and length of stays. Despite recent advances in supportive care and pre-conditioning regimens, complications are common and costly during HSCT.
- 3 August 2018
- Published by Taylor & Francis in Journal of Asthma
- Vol. 56 (8) , 872-881
A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma
Introduction: Poorly controlled severe eosinophilic asthma is difficult and costly to manage. Reslizumab, an add-on treatment for adults with severe eosinophilic asthma, reduces the number of exacerbations and improves the quality of life (QoL). The objective of this study was to evaluate the cost-effectiveness of reslizumab. Methods: A Markov model was used to compare the cost-effectiveness of add-on reslizumab with the standard-of-care (SOC) from the US societal perspective over a five-year time horizon. Efficacy and safety inputs for the model were based on data from two clinical trials (NCT01287039 and NCT01285323). Other model inputs, including mortality rates, costs, and utility, were estimated from literature, the Centers for Disease Control and Prevention (CDC), the US Department of Veterans Affairs (VA) and the Centers for Medicare and Medicaid Services (CMS). One-way, threshold, and probabilistic sensitivity analyses (PSA) were performed. Adherence, treatment response, and the placebo effect were evaluated in separate scenario analyses. Results: The base case incremental cost-effectiveness ratio (ICER) was $697 403 (2017 USD) per quality-adjusted life-years (QALYs). In the PSA, reslizumab becomes cost-effective in 50% of the iterations at a willingness-to-pay (WTP) threshold of $689 000. The model is most sensitive to the QoL improvement with reslizumab treatment in the one-way and threshold analyses. The response and adherence models had lower ICERs than the base model but still above $500 000. The ICER of the placebo effect model was $29 820. Conclusions: The improvement in QoL and exacerbation rates with reslizumab are associated with high costs, making reslizumab unlikely to be cost-effective at the $200 000 WTP threshold.
- 3 August 2018
- Published by Taylor & Francis in Journal of Asthma
- Vol. 56 (8) , 872-881
A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma
Introduction: Poorly controlled severe eosinophilic asthma is difficult and costly to manage. Reslizumab, an add-on treatment for adults with severe eosinophilic asthma, reduces the number of exacerbations and improves the quality of life (QoL). The objective of this study was to evaluate the cost-effectiveness of reslizumab. Methods: A Markov model was used to compare the cost-effectiveness of add-on reslizumab with the standard-of-care (SOC) from the US societal perspective over a five-year time horizon. Efficacy and safety inputs for the model were based on data from two clinical trials (NCT01287039 and NCT01285323). Other model inputs, including mortality rates, costs, and utility, were estimated from literature, the Centers for Disease Control and Prevention (CDC), the US Department of Veterans Affairs (VA) and the Centers for Medicare and Medicaid Services (CMS). One-way, threshold, and probabilistic sensitivity analyses (PSA) were performed. Adherence, treatment response, and the placebo effect were evaluated in separate scenario analyses. Results: The base case incremental cost-effectiveness ratio (ICER) was $697 403 (2017 USD) per quality-adjusted life-years (QALYs). In the PSA, reslizumab becomes cost-effective in 50% of the iterations at a willingness-to-pay (WTP) threshold of $689 000. The model is most sensitive to the QoL improvement with reslizumab treatment in the one-way and threshold analyses. The response and adherence models had lower ICERs than the base model but still above $500 000. The ICER of the placebo effect model was $29 820. Conclusions: The improvement in QoL and exacerbation rates with reslizumab are associated with high costs, making reslizumab unlikely to be cost-effective at the $200 000 WTP threshold.